Abstract
Although circulating microRNAs (miRNAs) were frequently detected in sera of cancer patients, there is still a lack of analysis of the dynamic changes of miRNAs expression in sera of pre- and post-operative lung carcinoma patients. Thus, we conducted quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to examine the expression of four miRNAs (miR-21, miR-205, miR-30d, and miR-24) in the sera of a set of 82 pre-operative lung carcinoma patients and paired 10 days post-operative patients, as well as in 50 normal volunteers. We showed that, compared to that in normal volunteers, the expression of miR-21, miR-205, miR-30d, and miR-24 was increased in lung cancer sera samples, as well as in sera of early stage lung cancer patients according to their clinical-pathological characteristics. The area under roc curves (AUCs) for levels of miR-21, miR-205, miR-30d, and miR-24 in sera were significantly higher than those for Carcinoma embryonic antigen (CEA) (P < 0.05), whereas the AUC for combination of serum levels of miRNA with serum CEA showed no significant difference from that for serum levels of miRNAs only (P > 0.05). The expression levels of miR-21 and miR-24 were significantly decreased in post-operative sera compared with levels in paired pre-operative sera (P = 0.0004 and <0.0001, respectively). In addition, high expressions of miR-21 and miR-30d in pre-operative sera were independently correlated with shorter overall survival in lung cancer patients (log-rank test: P = 0.0498, 0.0019). In summary, our results suggest that miR-21, miR-205, miR-30d, and miR-24 may serve as potential novel non-invasive biomarkers for diagnosis of lung cancer. In addition, miR-21 and miR-24 serum levels were lower in post-operative samples than those in pre-operative samples, suggesting they can potentially be used as biomarkers for disease recurrence after surgery operation.
Similar content being viewed by others
References
Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Yang L, et al. Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer. 2004;90:2157–66.
Verdecchia A, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–96.
Boeri M, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108:3713–8.
Chen X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.
Hu Z, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–6.
Chen X, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for non-small cell lung cancer diagnosis. In J Cancer. 2012;130:1620–8.
Keller A, et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 2011;8:506–16.
Liu XG, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29:618–26.
Lebanony D, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non–small-cell lung carcinoma. J Clin Oncol. 2009;27:2030–7.
Xie L, et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer. 2010;10:591–6.
Huang Z, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. In J Cancer. 2010;127:118–26.
Wang J, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res. 2009;2:807–13.
Heneghan HM, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.
Zheng H, et al. Define relative incomplete resection by highest mediastinal lymph node metastasis for non-small cell lung cancers: rationale based on prognosis analysis. Lung Cancer. 2011;72:348–54.
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.
Zheng D, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4:575–86.
Frezzetti D, et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene. 2010;30:275–86.
Ma X, et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA. 2011;108:10144–9.
Hatley ME, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18:282–93.
Seike M, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA. 2009;106:12085–90.
Zhou X, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010;90:144–55.
Kumar M, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 2010;30:843–53.
Yao J, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010;51:846–56.
Qin W, et al. MiR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One. 2010;5:e9429.
Majid S, et al. MicroRNA-205 directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer. 2010;116:5637–49.
Cheng H, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6:e17745.
Duttagupta R, et al. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6:e20769.
Lodes MJ, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4:e6229.
Del Vescovo V, et al. miR-205 Expression levels in non-small cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. 2011;35:268–75.
Acknowledgments
This research was supported by the Science and Technology Program of Zhoushan (No.091042, No. 2011C12039) and the Grants from Medical Bureau of Zhejiang Province (No. 2009A210).
Conflict of interest
The authors declare no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Han-Bo Le, Wang-Yu Zhu, and Dong-Dong Chen are equally contributed to this manuscript.
Rights and permissions
About this article
Cite this article
Le, HB., Zhu, WY., Chen, DD. et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol 29, 3190–3197 (2012). https://doi.org/10.1007/s12032-012-0303-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-012-0303-z